Arielle Yablonovitch
Guardant (United States)(US)
Publications by Year
Research Areas
Cancer Genomics and Diagnostics, PARP inhibition in cancer therapy, BRCA gene mutations in cancer, DNA Repair Mechanisms, Pancreatic and Hepatic Oncology Research
Most-Cited Works
- → Fluorescent indicators for simultaneous reporting of all four cell cycle phases(2016)223 cited
- → RNA sequencing reveals a diverse and dynamic repertoire of the Xenopus tropicalis transcriptome over development(2012)152 cited
- → The evolution and adaptation of A-to-I RNA editing(2017)136 cited
- → A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors(2021)91 cited
- → Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer(2024)61 cited
- → Regulation of gene expression and RNA editing in Drosophila adapting to divergent microclimates(2017)61 cited
- → Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14∆).(2020)33 cited
- → The Role of Abcb5 Alleles in Susceptibility to Haloperidol-Induced Toxicity in Mice and Humans(2015)29 cited
- → The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib(2023)21 cited
- → Identification of FGFR2/3 fusions from clinical cfDNA NGS using a de novo fusion caller.(2020)4 cited